Chapter review

Fitzgerald PMHNP board review. ch08. Mood Disorders. This is drive 7 of 8. When I say Pause. Answer. wait, then I will give the answer. New section. Medical rule-outs, suicide risk, peripartum/special populations, and board traps. Topic. Suicide Risk Assessment. Bottom Line Summary. * **Recurrent Thoughts of Death or Ideation**: Diagnostic criteria for **major depressive disorder** require at least 5 of 9 **SIG E CAPS** symptoms for a minimum duration of 2 weeks, where the letter R represents recurrent thoughts of death, passive suicidal ideation, active planning, or suicide attempts. * **Independent Anti-Suicidal Properties**: **Lithium** and **clozapine** are the only two psychiatric medications proven to independently reduce suicide risk in patients with mood and psychotic disorders. * **FDA Black Box Warning**: **SSRIs** carry an FDA boxed warning for increased suicidal ideation in children, adolescents, and young adults up to age 24. This warning specifies an increase in suicidal thoughts, not an increase in completed suicides. * **Lethality in Overdose**: Tricyclic antidepressants such as **amitriptyline** present a high risk of fatal overdose due to severe cardiac conduction toxicity and arrhythmias, whereas **SSRIs** and **SNRIs** have a significantly wider therapeutic window. * **Emergency Intervention Standards**: **Electroconvulsive therapy** (**ECT**) is a first-line non-pharmacologic intervention for life-threatening suicidality, severe depression with acute refusal of food or fluids, and severe depression during pregnancy. * **Bipolar Illness Timing**: Patients with **bipolar disorder** are at the highest risk for suicide attempts during major depressive or mixed episodes, rather than during periods of pure euphoric mania. * **High-Risk Recurrence Markers**: Factors that significantly increase depression recurrence and ongoing suicide risk include prior depressive episodes, early age of onset, co-occurring anxiety disorders, and co-occurring chronic medical conditions like diabetes mellitus. High-Yield Concept Review: Suicide Risk Assessment. Clinical Assessment Sequence and Risk Stratification. Suicide risk assessment is an essential component of every psychiatric evaluation. In the **DSM-5-TR** framework, suicidal ideation is evaluated under the **SIG E CAPS** diagnostic criteria for **major depressive disorder**. Passive suicidal ideation, such as wishing to go to sleep and not wake up, is the most common presentation in outpatient clinical settings. Active suicidal ideation involves explicit thoughts of self-harm, a specific plan, intent, or accessible lethal means. **First-Line**: When a patient reports active suicidal ideation, your primary clinical priority is to assess immediate physical safety, determine the presence of a concrete plan and lethal means, and select the appropriate care setting, such as inpatient psychiatric admission versus outpatient safety planning. **Safety Alert**: If a patient in an outpatient setting expresses active suicidal ideation with a intent and access to lethal means, such as a firearm in the home, you must secure immediate safety, arrange emergency evaluation, and never leave the patient unmonitored. Standard outpatient medication adjustments or routine follow-up scheduling are unsafe as initial steps. Protective Factors and Risk Modifiers. Assessment requires balancing individual risk factors against protective factors. * Key protective factors identified in board prep courses include personal resilience, strong social support systems, active religious or spiritual beliefs, and positive therapeutic rapport. * Key longitudinal risk factors for recurrent depression and associated suicide risk include a history of multiple prior depressive episodes, early onset of mood symptoms in adolescence or early adulthood, comorbid anxiety disorders, comorbid substance use disorders, and co-occurring chronic physical illnesses such as diabetes. Pharmacotherapy and Safety Pearls. **Lithium** is a foundational mood stabilizer that possesses independent anti-suicidal properties. In patients with **bipolar disorder** or severe recurrent **major depressive disorder**, retaining or initiating **lithium** provides documented protection against suicide attempts and completed suicide. **Clozapine** is the second agent with demonstrated independent efficacy in reducing suicidal behavior, specifically in patients with **schizophrenia** or **schizoaffective disorder**. **Board Trap**: Test writers often attempt to trick test-takers into choosing **amitriptyline** or other tricyclic antidepressants for depressed patients with chronic pain or insomnia. Remember that tricyclic antidepressants carry a high risk of lethal cardiac toxicity in overdose. Prescribing a 30-day supply of a tricyclic antidepressant to a patient with active or historical suicidal ideation is dangerous; **SSRIs** or **SNRIs** are much safer first-line choices due to their higher therapeutic index. **Safety Alert**: **SSRIs** carry an explicit FDA boxed warning for individuals up to age 24 regarding increased suicidal ideation during the initial weeks of treatment. When initiating an **SSRI** in adolescents or young adults, counsel the patient and family regarding early monitoring, weekly check-ins during initial titration, and signs of agitation or worsening distress. Bipolar Disorder and Special Populations. In patients with **bipolar disorder**, suicide risk is unevenly distributed across phase presentations. **Board Trap**: A common misconception is that patients with **bipolar disorder** are most likely to attempt suicide during severe manic episodes due to impulsivity. Board exams specifically test the fact that suicide attempts occur most frequently during depressed phases or mixed states, where profound despair coexists with elevated psychomotor energy. For pregnant or lactating patients with severe, life-threatening suicidal ideation or food refusal, **electroconvulsive therapy** (**ECT**) is safe, highly effective, and acts rapidly to stabilize acute life-threatening risk when medications are contraindicated or ineffective. Board-Style Practice Scenarios. Question 1. A 26-year-old married woman with a 2-year-old daughter presents for evaluation of depression that she believes began after the birth of her daughter. She has a Beck Depression Inventory score of 23, indicating moderate depression. She relates that she is overall healthy and is currently 16 weeks pregnant. Which of the following would NOT be an appropriate course of action? A. Advise no medication or psychotherapy at this time B. Refer for weekly interpersonal psychotherapy C. Initiate therapy with a therapeutic dose of citalopram D. Prescribe a therapeutic dose of sertraline **Pause. Answer: A** **Why It Is Correct**: Option A is inappropriate because leaving moderate depression untreated in a pregnant patient exposes both mother and fetus to significant psychiatric and developmental risks. Interventions such as evidence-based psychotherapy or appropriate **SSRI** pharmacotherapy are clinically indicated. **Why the Other Choices Are Wrong**: * **A**: Correct answer to the negative stem, as taking no action is unsafe. * **B**: Incorrect choice to select because interpersonal psychotherapy is an evidence-based, safe first-line treatment for mild to moderate depression during pregnancy. * **C**: Incorrect choice to select because **citalopram** is an acceptable **SSRI** option when the clinical benefit outweighs potential risks. * **D**: Incorrect choice to select because **sertraline** is one of the most widely studied and preferred **SSRIs** in pregnancy and lactation. Question 2. An overdose of which of the following medications is most likely to be fatal? A. Amitriptyline B. Duloxetine C. Fluoxetine D. Bupropion **Pause. Answer: A** **Why It Is Correct**: **Amitriptyline** is a tricyclic antidepressant. Tricyclic antidepressants cause severe cardiotoxicity, sodium channel blockade, lethal cardiac arrhythmias, and central nervous system depression in acute overdose, making them vastly more dangerous than newer antidepressant classes. **Why the Other Choices Are Wrong**: * **A**: Correct option. * **B**: Incorrect because **duloxetine**, an **SNRI**, has a significantly wider therapeutic index and is substantially less cardiotoxic in overdose. * **C**: Incorrect because **fluoxetine**, an **SSRI**, is relatively safe in acute overdose when ingested as a single agent. * **D**: Incorrect because while **bupropion** lowers the seizure threshold at high doses, it lacks the severe fatal cardiotoxicity associated with tricyclic antidepressant overdoses. Question 3. A 22-year-old male with type 1 diabetes mellitus and generalized anxiety disorder is currently being successfully treated for recurrent major depressive disorder. He has been symptom-free for the past 6 months on sertraline and asks if he can discontinue his medication. You counsel him that he has a high risk of depression recurrence due to which of the following factors? A. Past history of depressive episodes B. Presence of a chronic general medical condition C. Co-occurring generalized anxiety disorder D. His young age at presentation **Pause. Answer: All options (A, B, C, and D) represent valid risk factors** **Why It Is Correct**: National certification review guidelines specify that risk of depression recurrence is elevated by a history of multiple prior episodes, early age of onset, co-occurring non-affective psychiatric conditions like anxiety, and chronic general medical illnesses like type 1 diabetes. **Why the Other Choices Are Wrong**: * **A**: Correct risk factor because a history of recurrent episodes is one of the strongest predictors of future relapse. * **B**: Correct risk factor because chronic physical conditions like diabetes increase neurobiological and psychosocial vulnerability to depression. * **C**: Correct risk factor because comorbid anxiety disorders double the risk of depressive recurrence and complicate treatment response. * **D**: Correct risk factor because an earlier age of onset correlates with a more recurrent longitudinal illness course. Question 4. Which statement accurately describes suicide risk in a patient diagnosed with bipolar spectrum disorder? A. Suicide attempts occur most frequently during severe euphoric manic episodes B. Suicide attempts occur most frequently during depressive or mixed episodes C. Maintenance lithium therapy is contraindicated in patients with a history of suicidal intent D. Psychotropic medications should be discontinued immediately if passive ideation is reported **Pause. Answer: B** **Why It Is Correct**: In **bipolar disorder**, the vast majority of suicide attempts and completed suicides occur during major depressive episodes or mixed states, where severe mood distress is accompanied by sufficient energy to act. **Why the Other Choices Are Wrong**: * **A**: Incorrect because pure euphoric mania carries a lower immediate risk of suicide attempt compared to depressed or mixed states. * **B**: Correct option. * **C**: Incorrect because **lithium** has proven independent anti-suicidal properties and is specifically indicated to prevent suicidal behavior in bipolar illness. * **D**: Incorrect because passive ideation requires thorough risk assessment and ongoing mood stabilization, not abrupt discontinuation of essential mood stabilizers. Question 5. Which of the following interventions is considered first-line for a pregnant patient presenting with severe major depressive disorder, acute psychotic features, and active life-threatening refusal of food and fluids? A. High-dose oral fluoxetine monotherapy B. Electroconvulsive therapy C. Weekly outpatient supportive psychotherapy D. Transcranial magnetic stimulation **Pause. Answer: B** **Why It Is Correct**: **Electroconvulsive therapy** (**ECT**) is safe in pregnancy and is the gold standard, rapid-acting treatment for life-threatening psychiatric emergencies, including severe suicidal starvation, severe catatonia, and psychotic depression. **Why the Other Choices Are Wrong**: * **A**: Incorrect because oral antidepressants require 4 to 8 weeks for therapeutic effect, which is unacceptably slow for an acute life-threatening medical emergency. * **B**: Correct option. * **C**: Incorrect because outpatient psychotherapy alone is ineffective and unsafe for severe psychotic depression with acute medical compromise. * **D**: Incorrect because transcranial magnetic stimulation is not indicated for acute life-threatening emergency stabilization or psychotic depression. I hope this focused study review helps you master suicide risk assessment and board safety logic. What topic or chapter would you like to review next? Next. Topic. Peripartum vs Baby Blues. Bottom Line Summary. - **Baby blues** is a mild, self-limiting mood disturbance peaking 3 to 5 days postpartum and resolving within **10 to 14 days** (2 weeks), affecting up to 80% of new mothers without causing severe functional disruption. - **Major depressive disorder with peripartum onset** requires meeting full DSM-5-TR MDD criteria of at least **5 SIGECAPS symptoms** for at least **2 weeks**, with symptom onset occurring during pregnancy or within the first **4 weeks postpartum**. - **Postpartum psychosis** is a psychiatric emergency occurring in **1 to 2 per 1,000** deliveries, presenting rapidly within **2 to 3 weeks postpartum** with mania, confusion, hallucinations, and infant-focused delusions. - **First-line** treatment for mild to moderate peripartum depression is evidence-based psychotherapy, specifically **interpersonal psychotherapy (IPT)** or **cognitive behavioral therapy (CBT)**. - **First-line** pharmacotherapy for moderate to severe peripartum depression includes **sertraline** or **citalopram**, with **sertraline** preferred during lactation due to low excretion into breast milk (**Hale Category L2**). - **Safety alert:** **Lithium** is contraindicated during lactation (**Hale Category L4**) due to high infant blood levels, risk of toxicity, and fluid balance disruptions. - **Board trap:** Do not choose watchful waiting or "no treatment" for a pregnant patient with moderate depression score, as untreated depression poses serious risks of preterm labor, low birth weight, and poor maternal bonding. Peripartum Mood Continuum. Baby Blues. - **What it is:** Transient, non-pathological emotional lability following delivery. - **Timeline:** Onset within 2 to 3 days postpartum, peaking at day 3 to 5, and resolving spontaneously within 10 to 14 days. - **Must-know features:** Characterized by tearfulness, mild anxiety, irritability, and mood swings. Daily functioning remains intact. - **First-line:** Supportive care, reassurance, education, and assistance with sleep hygiene. Psychotropics are not indicated. Major Depressive Disorder with Peripartum Onset. - **What it is:** Major depressive episode occurring during gestation or in the early postpartum period. - **Timeline:** DSM-5-TR specifier requires symptom onset during pregnancy or within 4 weeks after childbirth, though clinical presentation can occur throughout the first postpartum year. Symptoms must last at least 2 weeks. - **Must-know features:** Requires 5 or more SIGECAPS criteria, including mandatory depressed mood or anhedonia, accompanied by guilt, sleep disturbance, or fatigue. - **First-line:** Non-pharmacologic approaches like IPT or CBT for mild to moderate severity. SSRIs such as **sertraline** or **citalopram** when pharmacotherapy is necessary. - **Safety alert:** Maternal depression must be treated; leaving mood disorders unmanaged during pregnancy increases fetal and maternal morbidity. Postpartum Psychosis. - **What it is:** Severe, acute psychotic mood episode, most commonly an expression of underlying bipolar spectrum disorder. - **Timeline:** Onset is typically abrupt, occurring within 2 to 3 weeks after delivery. - **Must-know features:** Depersonalization, severe insomnia, mood lability, auditory hallucinations, and delusional beliefs regarding the infant (such as baby being possessed or defective). - **Safety alert:** Requires immediate psychiatric evaluation and emergency inpatient hospitalization due to extreme risk of infanticide or maternal suicide. Compare and Distinguish. Baby Blues vs. Peripartum Depression - **Think:** Blues is brief tearfulness that resolves by two weeks; peripartum depression is persistent functional impairment lasting beyond two weeks. - **Priority:** Monitor duration. If mood symptoms extend past 14 days, re-screen using the PHQ-9 or Edinburgh Postnatal Depression Scale to diagnose peripartum depression. - **Boards are testing:** Recognizing the 2-week cutoff where normal transitional blues becomes a treatable clinical depression. Obsessive Intrusive Thoughts vs. Postpartum Psychosis - **Think:** Intrusive harm thoughts in postpartum OCD/depression are egodystonic and cause extreme maternal distress; psychotic delusions are egosyntonic beliefs that lead to unsafe actions. - **Priority:** Assess reality testing and intent. Egodystonic fear of harming the baby requires anxiety/depression management; egosyntonic delusional beliefs require immediate emergency admission. - **Board trap:** Mistaking severe maternal anxiety and intrusive fears for psychosis, leading to inappropriate involuntary commitment or unnecessary medication changes. Prescribing and Safety Pearls. - **First-line in pregnancy:** **Sertraline** and **citalopram** have extensive safety data demonstrating low overall teratogenic risk. - **First-line in lactation:** **Sertraline** is the preferred SSRI during breastfeeding due to minimal drug levels transfer into human breast milk. - **Safety alert:** **Lithium** carries a Hale Category L4 rating in lactating mothers because infant renal clearance is immature, creating a high risk of infant lithium toxicity and severe dehydration. Sample Practice Question. Question 8. A 26-year-old married woman with a 2-year-old daughter presents for evaluation of depression that she believes began after the birth of her daughter. She has a BDI score of 23. She relates that she is overall healthy and that she is 16 weeks pregnant. Which of the following would not be an appropriate course of action? A. Advise no medication or psychotherapy at this time B. Refer for weekly interpersonal psychotherapy C. Initiate therapy with a therapeutic dose of citalopram D. Prescribe a therapeutic dose of sertraline Pause. Answer. **Best Answer:** A. Advise no medication or psychotherapy at this time **Why It Is Correct:** A Beck Depression Inventory (BDI) score of 23 indicates moderate depression. Advising no intervention is incorrect clinical management because untreated depression during pregnancy carries serious risks to both the mother and fetus, including poor prenatal care, preterm labor, low birth weight, and postpartum complications. Moderate depression requires active intervention. **Why the Other Choices Are Wrong:** - **A:** This choice is incorrect clinical care because withholding treatment leaves a moderately depressed pregnant woman at risk. - **B:** Interpersonal psychotherapy (IPT) is an evidence-based first-line psychotherapeutic intervention for mild to moderate peripartum depression. - **C:** Citalopram is an SSRI with documented safety and efficacy during pregnancy when medication is warranted. - **D:** Sertraline is an evidence-based first-line SSRI in pregnancy and lactation with an established safety profile. Next. Topic. Postpartum Psychosis. Bottom Line Summary. * **Peripartum onset specifier** applies to mood symptoms occurring during pregnancy or within the first **4 weeks** following delivery [1, 2]. * **Postpartum psychosis** is a medical emergency strongly associated with underlying **bipolar disorder**, presenting with severe affective lability, delusions, and hallucinations source 3. * Immediate hospitalization and safety stabilization are mandatory because **postpartum psychosis** carries high risk for infanticide and suicide [4, 5]. * **Interpersonal psychotherapy** is **first-line** non-pharmacologic treatment for mild to moderate peripartum depression [6-9]. * **Sertraline** and **citalopram** are preferred SSRIs during pregnancy and lactation, whereas doing nothing for moderate depression is unsafe [6-8]. * **Lithium** is categorized under Hale's Lactation Risk Category **L4** (hazardous) and is contraindicated during breastfeeding due to infant toxicity risks [10-14]. * **Electroconvulsive therapy** is a safe, highly effective treatment for severe, psychotic, or life-threatening suicidal peripartum mood episodes [15, 16]. * Novel neuroactive steroids for postpartum depression include **brexanolone** (intravenous infusion) and **zuranolone** (oral formulation), which act as GABA-A receptor allosteric modulators [17, 18]. High-Yield Concept Map & Spoken Teaching. Diagnostic Criteria and Timelines. * The DSM-5-TR defines the **peripartum onset** specifier as symptom onset during pregnancy or within **4 weeks** after childbirth [1, 2]. * **Postpartum psychosis** develops rapidly within days to weeks postpartum, exhibiting rapid mood shifts, disorientation, paranoia, and delusions often focused on the newborn source 3. * Most cases of **postpartum psychosis** represent an acute presentation of **bipolar disorder** triggered by dramatic hormonal shifts and sleep deprivation [3, 19]. Safety and Risk Management. * **Safety alert**: **Postpartum psychosis** is an absolute psychiatric emergency source 4. Delusions regarding infant contamination or possession create extreme risk for infanticide or suicide, requiring immediate inpatient psychiatric admission and continuous observation [4, 5]. * **Board trap**: Avoid misdiagnosing **postpartum psychosis** as brief "postpartum blues." Postpartum blues are mild, self-limiting, and resolve within 10 to 14 days without functional impairment or psychotic features, whereas psychosis requires immediate antipsychotic or mood stabilizer intervention [3, 20]. * **Board trap**: Avoid assuming psychotropic medications or ECT cannot be used in pregnant or lactating patients. Untreated maternal depression carries significant risks of low birth weight, premature delivery, and impaired bonding [6-8]. Pharmacotherapy and Interventions. * **First-line**: **Interpersonal psychotherapy** (IPT) is the preferred non-pharmacologic treatment for mild to moderate peripartum depression [6-9]. * **First-line**: When pharmacotherapy is necessary for moderate to severe peripartum depression, **sertraline** or **citalopram** are well-supported choices [6-8]. * **Safety alert**: **Lithium** is classified as Hale's Lactation Risk Category **L4** [10-14]. It passes directly into breast milk, creating severe risks of infant dehydration, electrolyte disturbance, and renal toxicity [10-14]. * **Electroconvulsive therapy** (ECT) remains one of the safest and fastest treatments for pregnant patients presenting with severe psychotic depression, acute mania, or active suicidality [15, 16]. * **Brexanolone** is administered as a 60-hour intravenous infusion under continuous pulse oximetry monitoring due to risks of sudden sedation and loss of consciousness [17, 18]. **Zuranolone** provides a 14-day oral course for postpartum depression source 18. Fitzgerald Sample Test Questions. Question 1. A 26-year-old married woman with a 2-year-old daughter presents for evaluation of depression that she believes began after the birth of her daughter . She has a Beck Depression Inventory score of 23 . She relates that she is overall healthy and that she is 16 weeks pregnant . Which of the following would not be an appropriate course of action ? * A. Advise no medication or psychotherapy at this time * B. Refer for weekly interpersonal psychotherapy * C. Initiate therapy with a therapeutic dose of citalopram * D. Prescribe a therapeutic dose of sertraline Quick Answer. Advising no treatment is inappropriate because moderate peripartum depression requires active clinical management . Key Clue. 16 weeks pregnant with a BDI score of 23 indicating moderate depression . Best Answer. A. Advise no medication or psychotherapy at this time . Why It Is Correct. A BDI score of 23 reflects moderate depression . Leaving moderate maternal depression untreated increases risks of adverse fetal and maternal outcomes, making inaction non-standard and unsafe care . Why the Other Choices Are Wrong. * **A:** This choice is the correct response to the negative stem because doing nothing is inappropriate . * **B:** Interpersonal psychotherapy is an evidence-based first-line non-pharmacologic option during pregnancy . * **C:** Citalopram is a reasonable SSRI option when pharmacotherapy is indicated in pregnancy . * **D:** Sertraline is an appropriate, widely studied SSRI choice in peripartum care . Test-Taking Pearl. Always intervene when a pregnant patient presents with moderate-to-severe depression; leaving maternal mood disorders untreated is a dangerous distractor . Question 2. There is positive evidence that the use of lithium by a breastfeeding woman can pose a risk to the infant . This medication meets Hale's lactation risk category : * A. L1 * B. L2 * C. L3 * D. L4 Quick Answer. Lithium is classified as Hale's L4 (hazardous) during lactation source 10. Key Clue. Breastfeeding woman taking lithium . Best Answer. D. L4 . Why It Is Correct. Lithium is excreted in high concentrations into breast milk and poses substantial risks of infant fluid and electrolyte toxicity, placing it squarely in Hale's Lactation Risk Category L4 source 10. Why the Other Choices Are Wrong. * **A:** L1 designates safest medications with extensive human data showing no infant risk source 21. * **B:** L2 designates safer drugs studied in limited cohorts without documented adverse effects, such as most SSRIs source 21. * **C:** L3 designates moderately safe or controlled drugs where risks are possible but less clear than L4 source 10. * **D:** L4 is the correct category for lithium because clear evidence demonstrates significant hazardous potential source 10. Test-Taking Pearl. Memorize that lithium is L4 in lactation; breastfeeding must be discontinued if lithium therapy is mandatory source 10. Next Study Step. Proceed to **Fitzgerald Chapter 9: Anxiety Disorders**, focusing on differentiating **generalized anxiety disorder**, **panic disorder**, and **OCD** from medical mimics like hyperthyroidism and pheochromocytoma [22, 23]. Next. Topic. Pediatric Mood Presentation. Bottom Line Summary. * In children and adolescents with **major depressive disorder**, core mood disruption frequently manifests as **irritability** rather than depressed mood, described clinically as a "mad at the world" outlook. * Pediatric physical criteria for **major depressive disorder** includes a **failure to make expected weight gain** rather than classic weight loss or weight gain. * Diagnostic timelines for **persistent depressive disorder** (dysthymia) and **cyclothymic disorder** are shortened to **1 year** in children and adolescents, compared to **2 years** in adults. * Maximum allowable symptom-free duration for both **persistent depressive disorder** and **cyclothymic disorder** is **2 months** across all age groups. * The incidence of **bipolar disorder** in children and adolescents is **1%**, where mania or hypomania presents as developmental **giddiness, happiness, or silliness** distinctly elevated above baseline. * All SSRIs carry an FDA **black box warning** for increased **suicidal ideation** in children, adolescents, and young adults up to age **24**. * **Fluoxetine** has an extended half-life of 84 hours for the parent drug and 7 to 15 days for its active metabolite **norfluoxetine**, providing a safety buffer when doses are occasionally missed. * **First-line** treatment for mild to moderate pediatric depression is psychotherapy such as **cognitive behavioral therapy** or **interpersonal psychotherapy**, while moderate to severe cases require combining psychotherapy with an SSRI. Spoken Study Teaching: Pediatric Mood Presentation. Clinical Features of Pediatric Depression. When evaluating mood disorders in pediatric populations, clinicians must adapt adult DSM-5-TR criteria to developmental equivalents. In children and adolescents experiencing a major depressive episode, depressed mood often presents as persistent **irritability**, angry outbursts, or a pervasive hostility toward peers, teachers, and family. Vegetative signs also differ in growing youth. While adults demonstrate explicit weight loss or weight gain, pediatric patients frequently manifest appetite changes as a **failure to make expected weight gain** for their growth curve. For chronic depressive presentations, the diagnostic threshold for **persistent depressive disorder** (dysthymia) requires symptoms for at least **1 year** in children and adolescents, rather than the **2 years** required for adults. Throughout that 1-year period, symptoms cannot be absent for more than **2 months** at a time. **Board trap:** Do not misdiagnose a child presenting with chronic irritability as having oppositional defiant disorder or conduct disorder without screening for underlying mood pathology. Chronic irritability is a primary depression equivalent in youth. Additionally, do not fail pediatric board questions by requiring 2 years of symptoms for dysthymia; remember the shortened 1-year timeline for children and adolescents. Pediatric Bipolar and Cyclothymic Presentations. **Bipolar disorder** has an estimated incidence of **1%** in children and adolescents. Diagnosing manic or hypomanic episodes in pediatric patients requires distinguishing normal childhood energy from pathological mood elevation. In youth, the elevated or expansive mood criterion may present as intense **giddiness, happiness, or silliness** that is distinctly elevated beyond the child's typical baseline. This mood presentation must occur alongside persistently increased goal-directed activity or energy, exist in inappropriate social contexts, and exceed what is developmentally expected. For **cyclothymic disorder**, children and adolescents experience fluctuating periods of hypomanic symptoms and depressive symptoms for at least **1 year** (compared to **2 years** in adults). Symptoms must be present for at least half the time, with no symptom-free interval exceeding **2 months**. **Board trap:** Never assume pediatric mania requires adult-style grandiosity or financial spending sprees. Look for cyclic, out-of-context silliness, decreased need for sleep, and marked surges in activity that disrupt school or family life. Pharmacotherapy and Safety Warnings. When selecting pharmacotherapy for pediatric and young adult mood disorders, safety monitoring is the top priority. **Safety alert:** All antidepressant medications, including SSRIs like **fluoxetine** and **sertraline**, carry a prominent FDA **black box warning** for an increased risk of **suicidal ideation** and suicidal behaviors in children, adolescents, and young adults up to age **24**. Test writers frequently emphasize that this warning reflects increased suicidal thoughts, not an increase in completed suicides. Close clinical monitoring is required during the initial 4 to 8 weeks of therapy. **First-line:** For mild to moderate pediatric depression, evidence-based psychotherapy such as **cognitive behavioral therapy** (CBT) or **interpersonal psychotherapy** (IPT) is the primary first-line intervention. For severe depression, combining an SSRI with psychotherapy represents the gold standard standard of care. **Fluoxetine** is frequently selected in younger populations because of its forgiving pharmacokinetic profile. The half-life of **fluoxetine** is approximately 84 hours, while its active metabolite **norfluoxetine** has a half-life ranging from 7 to 15 days. This prolonged clearance minimizes abrupt drug level drops and protects against withdrawal or discontinuation syndrome if a young patient occasionally forgets a dose. Board Practice Questions. Question 1. Which of the following patients in need of an antidepressant is the best candidate for **fluoxetine** therapy? A) An 80-year-old woman taking multiple medications who presents with depressed mood and agitation B) A 45-year-old man with anorgasmia who is an occasional marijuana user C) A 28-year-old woman who occasionally skips a dose of her prescribed medication and uses a progestin implant for contraception D) A 44-year-old woman with decreased appetite who is taking hydrochlorothiazide for hypertension **Pause. Answer:** C **Why It Is Correct:** **Fluoxetine** possesses an exceptionally long half-life, with the parent compound having a half-life of 84 hours and its active metabolite, **norfluoxetine**, lasting 7 to 15 days. This long half-life provides a protective cushion for patients who occasionally miss doses without triggering rapid drug level drops or discontinuation symptoms. Clinicians must remember that **fluoxetine** carries an FDA **black box warning** for increased **suicidal ideation** in children, adolescents, and young adults up to age **24**, requiring close monitoring during initial titration. **Why the Other Choices Are Wrong:** * **A:** Older adults taking multiple medications should avoid **fluoxetine** due to its potent inhibition of CYP2D6 and CYP3A4 isoenzymes, which causes significant drug interactions, and its propensity to worsen agitation. * **B:** **Fluoxetine** and other SSRIs frequently cause sexual dysfunction, including anorgasmia and delayed ejaculation, making it a poor choice for a patient already experiencing anorgasmia. * **D:** **Fluoxetine** commonly causes anorexia and weight loss as initial side effects, which would exacerbate this patient's existing decreased appetite. Question 2. A 26-year-old married woman with a 2-year-old daughter presents for evaluation of depression that she believes began after the birth of her daughter. She has a Beck Depression Inventory score of 23, relates overall good health, and is 16 weeks pregnant. Which of the following would not be an appropriate course of action? A) Advise no medication or psychotherapy at this time B) Refer for weekly interpersonal psychotherapy C) Initiate therapy with a therapeutic dose of citalopram D) Prescribe a therapeutic dose of sertraline **Pause. Answer:** A **Why It Is Correct:** Advising no treatment for a pregnant patient presenting with symptomatic depression and a Beck Depression Inventory score of 23 (indicating moderate depression) is inappropriate and unsafe. Untreated maternal depression carries significant risks for both mother and fetus. Interpersonal psychotherapy or pharmacotherapy with safer SSRIs such as **sertraline** or **citalopram** are appropriate evidence-based options. **Why the Other Choices Are Wrong:** * **B:** Psychotherapy, specifically interpersonal therapy or CBT, is an effective and appropriate first-line treatment for mild to moderate depression during pregnancy. * **C:** **Citalopram** is an acceptable SSRI option during pregnancy when benefits outweigh risks after patient education and informed consent. * **D:** **Sertraline** is one of the most widely studied and preferred SSRIs during pregnancy and lactation due to low fetal and breastmilk transfer. 💡 *Want to quiz yourself on the next topic? We can dive into peripartum mood specifiers, bipolar treatment algorithms, or lab monitoring rules for mood stabilizers.* Next. End of this drive.